Bioverativ

Enjaymo

Manufacturer:

Bioverativ

Enjaymo HCPCS:

J1302

HCPCS Code Descriptor:

Injection, sutimlimab-jome, 10 mg

Category:

J Code

Enjaymo NDCs:

80203-0347-01

Primary Type:

Hematology

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Enjaymo:

Enjaymo is a Hematology drug manufactured by Bioverativ and administered via the Intravenous route of administration. The J Code: J1302 is aligned to the drug Enjaymo.

ACCESS PRICING AND MORE BY REGISTERING

J1302 Added Date:

October 1, 2022

J1302 Effective Date:

October 1, 2022

J1302 Termination Date:

HCPCS Active

Enjaymo billing and coding information can be found through Bioverativ at the link below:
Enjaymo patient assistance information can be found through ENJAYMO Patient Solutions at the URL: https://www.enjaymo.com/support-and-resources/patient-solutions
Enjaymo prescribing information can be found at the link below:
Information regarding Enjaymo’s side effects can be found at MedlinePlus